Moderna’s COVID Vaccine Sheds Negative Comparison On Myocarditis With BLA Approval

Unlike the current EUA fact sheet, Spikevax’s approved labeling does not state that the vaccine may pose an increased risk of myocarditis ‘relative to other authorized or approved mRNA COVID-19 vaccines.’ Approval brings Moderna a priority review voucher, as did Comirnaty’s approval for BLA sponsor BioNTech.

Trash disposal
Moderna was able to dispose of negative comparison safety language on myocarditis in its approved label, although it's still in the vaccine's EUA fact sheet. • Source: Alamy

Among the benefits for Moderna, Inc. in converting its COVID-19 vaccine emergency use authorization to an approved biologics license application was the ability to drop a negative comparison about myocarditis adverse events from its label.

Labeling for Spikevax, Moderna’s mRNA vaccine approved on 31 January, includes language in the warnings and precautions section about myocarditis...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet